HM97211

HM97211 is a novel, reversible small molecule inhibitor of Lysine-specific demethylase 1 (LSD1) being developed by Hanmi Pharmaceutical for the treatment of neuroendocrine-associated malignancies, including small cell lung cancer (SCLC) and acute myeloid leukemia (AML). LSD1 is an epigenetic enzyme that regulates gene expression by demethylating histone H3 lysine 4 (H3K4) and lysine 9 (H3K9); its dysregulation is associated with tumor survival and cell cycle progression. HM97211 functions by increasing global H3K4 methylation and downregulating the neuroendocrine transcription factor ASCL1, thereby inducing apoptosis and inhibiting tumor cell proliferation. Preclinical studies have demonstrated significant antitumor activity and tumor regression in SCLC xenograft models following oral administration, with a safety profile that suggests minimal impact on hematopoiesis differentiation compared to irreversible LSD1 inhibitors.